US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
GWA Group Ltd (GWA) 銘柄情報

GWA Group Ltd (GWA)

2.305

0.015

(0.66%)

終了 7月4日 3:00PM

GWA Group Ltd (GWA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.305

( 0.66% )

買値

2.29

売値

2.39

出来高

350,267

2.28 日の範囲 2.35

1.965 52 週間の範囲 2.79

時価総額

前日終値

2.29

始値

2.35

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 499,672

発行済株式数

256,629,413

配当利回り

0.16 (7.56%)

PER

12.8

1 株当たり利益 (EPS)

0.17

歳入

422.68M

純利益

46.56M

GWA Group Limited research, designs, manufactures, imports, and markets building fixtures and fittings to residential and commercial premises in Australia, New Zealand, the United Kingdom, and internationally. It provides vitreous China toilet suites, basins, plastic cisterns, taps and showers, kitc... GWA Group Limited research, designs, manufactures, imports, and markets building fixtures and fittings to residential and commercial premises in Australia, New Zealand, the United Kingdom, and internationally. It provides vitreous China toilet suites, basins, plastic cisterns, taps and showers, kitchen sinks, baths, laundry tubs, smart products, and bathroom accessories, as well as domestic water control valves under the Caroma, Methven, Dorf, and Clark brands. The company also distributes and installs various products through a range of distribution and customer channels. GWA Group Limited was incorporated in 1992 and is headquartered in Pinkenba, Australia. 詳細を表示

セクター

Consumer Discretionary

業界

Home And Homeware

ウェブサイト

www.gwagroup.com.au

本社

Pinkenba, Australia

設立

1992

GWA Group Ltd is listed in the Consumer Discretionary sector of the オーストラリア証券取引所 with ticker GWA. The last closing price for GWA was AUD2.29. Over the last year, GWA shares have traded in a share price range of AUD 1.965 to AUD 2.79.

GWA currently has 256,629,413 shares in issue. The market capitalisation of GWA is AUD591.53 million. GWA has a price to earnings ratio (PE ratio) of 12.80.

GWA Group Ltd: Here’s how you can get your hands on a slice of $88 million

http://www.fool.com.au/2015/04/24/gwa-group-ltd-heres-how-you-can-get-your-hands-on-a-slice-of-88-million/

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.055	2.44444444444	2.25	2.35	2.23	426109	2.28480191	DE
4	0.275	13.5467980296	2.03	2.38	2.02	533645	2.22576659	DE
12	0.145	6.71296296296	2.16	2.38	1.965	510891	2.11503663	DE
26	-0.235	-9.25196850394	2.54	2.74	1.965	430753	2.22723881	DE
52	-0.02	-0.860215053763	2.325	2.79	1.965	350724	2.33981332	DE
156	0.55	31.339031339	1.755	2.87	1.625	312962	2.28743952	DE
260	-0.445	-16.1818181818	2.75	2.96	1.6	333007	2.28962326	DE

GWA - Frequently Asked Questions (FAQ)

What is the current GWA Group Ltd share price?

The current share price of GWA Group Ltd is AUD 2.305

How many GWA Group Ltd shares are in issue?

GWA Group Ltd has 256,629,413 shares in issue

What is the market cap of GWA Group Ltd?

The market capitalisation of GWA Group Ltd is AUD 591.53M

What is the 1 year trading range for GWA Group Ltd share price?

GWA Group Ltd has traded in the range of AUD 1.965 to AUD 2.79 during the past year

What is the PE ratio of GWA Group Ltd?

The price to earnings ratio of GWA Group Ltd is 12.8

What is the cash to sales ratio of GWA Group Ltd?

The cash to sales ratio of GWA Group Ltd is 1.36

What is the registered address of GWA Group Ltd?

The registered address for GWA Group Ltd is Building 3B, Pinkenba, Queensland, 4008

What is the GWA Group Ltd website address?

The website address for GWA Group Ltd is www.gwagroup.com.au

Which industry sector does GWA Group Ltd operate in?

GWA Group Ltd operates in the Home and Homeware sector

williamssc

williamssc 3分前

Slide16 “Overall Conclusions: The survival benefit associated with DCVax-L treatment reflects a true treatment affect and was underestimated in the original analysis”

NASDAQ2020

NASDAQ2020 4分前

i will wait for Monday to grab some more ??

GoodGuyBill

GoodGuyBill 5分前

Brazen22, you’re trying to reduce three years of regulatory progress to one sentence: “You don’t have an approved MAA.”

Of course we don’t — yet. Approval is the destination. We have a validated MAA. What matters is whether NWBO has completed the steps that regulators require before a

NASDAQ2020

NASDAQ2020 5分前

THATS WHEN i ACCUMULATE. At The hammerbottom.

nowwhat2

nowwhat2 5分前

https://investorshub.advfn.com/uimage/uploads/2026/7/3/vwgethg_july_3_2y_plunge_sell.jpg

rizona

Slides! JAMA study UNDERESTIMATED survival benefit

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

rosemountbomber

rosemountbomber 8分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

chereb19

chereb19 8分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

NASDAQ2020

NASDAQ2020 9分前

Im glad I held my shares past $0.15

Idunno

Idunno 10分前

And don’t forget your buddy, AF. … .. .

Doc logic

Doc logic 10分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

rcaselli

rcaselli 10分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Idunno

Idunno 11分前

Have at it Brazen! ;) … .. . :)

CatfishHunter

CatfishHunter 13分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

asp42001

asp42001 13分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

BigBadWolf

BigBadWolf 13分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

mgland

mgland 15分前

https://x.com/thommic/status/2072760144774005081

GTF

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

manibiotech

manibiotech 17分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

ErnieBilco

ErnieBilco 18分前

Good to know because I was thinking about letting it go but now I have a reason to hold

gdog

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

AngeloFoca

AngeloFoca 19分前

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

rmoss

Stay away stay very far away........

flipper44

flipper44 21分前

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

stoxjock

stoxjock 21分前

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

Asian American Medical

Rafaella Resources

Interstar Mill SR05 2L

Renegade Exploration

Silverstock Metals

Western Ohio Financial

Metals Australia

Star Combo Pharma

Mejority Capital

RSE Collection (GM)

Deferred Settlement Trad...

Affiliated Resources (ID)

Resource Generation

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。